Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers

BACKGROUND: Mipomersen, an apolipoprotein B synthesis inhibitor, demonstrated significant reductions in low‐density lipoprotein (LDL) cholesterol, non‐high density lipoprotein cholesterol, and apolipoprotein B in 4 phase 3 studies at the FDA‐approved subcutaneous dose of 200 mg once weekly. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Flaim, JoAnn D., Grundy, John S., Baker, Brenda F., McGowan, Mary P., Kastelein, John J. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187476/
https://www.ncbi.nlm.nih.gov/pubmed/24627419
http://dx.doi.org/10.1161/JAHA.113.000560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187476/
https://www.ncbi.nlm.nih.gov/pubmed/24627419
http://dx.doi.org/10.1161/JAHA.113.000560

Ejemplares similares